These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The discovery of 4-{1-[({2,5-dimethyl-4-[4-(trifluoromethyl)benzyl]-3-thienyl}carbonyl)amino]cyclopropyl}benzoic acid (MK-2894), a potent and selective prostaglandin E2 subtype 4 receptor antagonist. Blouin M, Han Y, Burch J, Farand J, Mellon C, Gaudreault M, Wrona M, Lévesque JF, Denis D, Mathieu MC, Stocco R, Vigneault E, Therien A, Clark P, Rowland S, Xu D, O'Neill G, Ducharme Y, Friesen R. J Med Chem; 2010 Mar 11; 53(5):2227-38. PubMed ID: 20163116 [Abstract] [Full Text] [Related]
3. MF498 [N-{[4-(5,9-Diethoxy-6-oxo-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}-2-(2-methoxyphenyl)acetamide], a selective E prostanoid receptor 4 antagonist, relieves joint inflammation and pain in rodent models of rheumatoid and osteoarthritis. Clark P, Rowland SE, Denis D, Mathieu MC, Stocco R, Poirier H, Burch J, Han Y, Audoly L, Therien AG, Xu D. J Pharmacol Exp Ther; 2008 May 11; 325(2):425-34. PubMed ID: 18287210 [Abstract] [Full Text] [Related]
5. The discovery of 6-[2-(5-chloro-2-{[(2,4-difluorophenyl)methyl]oxy}phenyl)-1-cyclopenten-1-yl]-2-pyridinecarboxylic acid, GW848687X, a potent and selective prostaglandin EP1 receptor antagonist for the treatment of inflammatory pain. Giblin GM, Bit RA, Brown SH, Chaignot HM, Chowdhury A, Chessell IP, Clayton NM, Coleman T, Hall A, Hammond B, Hurst DN, Michel AD, Naylor A, Novelli R, Scoccitti T, Spalding D, Tang SP, Wilson AW, Wilson R. Bioorg Med Chem Lett; 2007 Jan 15; 17(2):385-9. PubMed ID: 17084082 [Abstract] [Full Text] [Related]
6. Effect of (S)-4-(1-(5-chloro-2-(4-fluorophenyoxy)benzamido)ethyl) benzoic acid (CJ-42794), a selective antagonist of prostaglandin E receptor subtype 4, on ulcerogenic and healing responses in rat gastrointestinal mucosa. Takeuchi K, Tanaka A, Kato S, Aihara E, Amagase K. J Pharmacol Exp Ther; 2007 Sep 15; 322(3):903-12. PubMed ID: 17578900 [Abstract] [Full Text] [Related]
11. 3-Acrylamide-4-aryloxyindoles: synthesis, biological evaluation and metabolic stability of potent and selective EP3 receptor antagonists. Zhou N, Zeller W, Zhang J, Onua E, Kiselyov AS, Ramirez J, Palsdottir G, Halldorsdottir G, Andrésson T, Gurney ME, Singh J. Bioorg Med Chem Lett; 2009 Mar 01; 19(5):1528-31. PubMed ID: 19188065 [Abstract] [Full Text] [Related]
12. 5-Lipoxygenase-activating protein inhibitors. Part 2: 3-{5-((S)-1-Acetyl-2,3-dihydro-1H-indol-2-ylmethoxy)-3-tert-butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-1H-indol-2-yl}-2,2-dimethyl-propionic acid (AM679)--a potent FLAP inhibitor. Stock N, Baccei C, Bain G, Broadhead A, Chapman C, Darlington J, King C, Lee C, Li Y, Lorrain DS, Prodanovich P, Rong H, Santini A, Zunic J, Evans JF, Hutchinson JH, Prasit P. Bioorg Med Chem Lett; 2010 Jan 01; 20(1):213-7. PubMed ID: 19914828 [Abstract] [Full Text] [Related]
13. Lactams as EP4 prostanoid receptor agonists. 3. Discovery of N-ethylbenzoic acid 2-pyrrolidinones as subtype selective agents. Elworthy TR, Brill ER, Chiou SS, Chu F, Harris JR, Hendricks RT, Huang J, Kim W, Lach LK, Mirzadegan T, Yee C, Walker KA. J Med Chem; 2004 Dec 02; 47(25):6124-7. PubMed ID: 15566283 [Abstract] [Full Text] [Related]